Oragenics partners Receptor.AI for brain health candidate portfolio [Yahoo! Finance]
Oragenics Inc. (OGEN)
NASDAQ:AMEX Investor Relations:
ir.oragenics.com
Company Research
Source: Yahoo! Finance
expedite the development of a new pharmaceutical candidate portfolio for brain health conditions. The partnership will leverage AI modelling techniques to determine the ideal receptor binding profiles for new compounds that Oragenics added to its portfolio in 2023. This approach is expected to streamline targeted lab validation as Oragenics seeks to broaden its scope beyond its primary candidate, ONP-002, which is currently undergoing clinical studies for concussion. The company is progressing with Phase IIa trials of ONP-002 in Australia and has plans to commence Phase IIb trials in the US. Receptor.AI's role will involve deploying its computational models to dissect the molecular structures of the compounds, aiming to identify the receptors that could potentially bind with therapeutic outcomes. The insights gained from AI analysis are expected to guide Oragenics in its laboratory testing procedures. This is expected to support the discovery of potential treatments for a ra
Show less
Read more
Impact Snapshot
Event Time:
OGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OGEN alerts
High impacting Oragenics Inc. news events
Weekly update
A roundup of the hottest topics
OGEN
News
- Oragenics Q3 2025 Shareholder UpdateBusiness Wire
- Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity DeficiencyBusiness Wire
- Oragenics announces partnership with Receptor.AI [Seeking Alpha]Seeking Alpha
- Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development [Yahoo! Finance]Yahoo! Finance
- Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline DevelopmentBusiness Wire
OGEN
Sec Filings
- 11/12/25 - Form 8-K
- 11/7/25 - Form 10-Q
- 10/21/25 - Form 8-K
- OGEN's page on the SEC website